Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease. (PubMed, J Prev Alzheimers Dis) - Oct 16, 2026 - "With the European authorisation of lecanemab and donanemab, Italy is entering the era of disease-modifying therapy for early symptomatic Alzheimer's disease. Strong agreement was reached on the large majority of statements, providing quantitative endorsement for a competence-based reorganisation of the CDCD network, the harmonised use of the Clinical Dementia Rating, an explicit composition of the multidisciplinary team, trial-aligned magnetic resonance imaging eligibility criteria with a move towards risk-adapted ARIA monitoring, and a stepwise biomarker pathway integrating plasma assays, cerebrospinal fluid analysis on automated platforms and amyloid positron emission tomography. The document provides Italian regional and national health systems, prescribing centres and reimbursing authorities with a quantitative blueprint for the appropriate, equitable and sustainable use of anti-amyloid monoclonal antibodies in clinical practice."
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders
|
|
Alba Rosa Alfano; Alberto Benussi; Alessandra Splendiani; Alessandro Padovani; Alessandro Tessitore; Andrea Falini; Andrea Ungar; Annachiara Cagnin; Antonio Antico; Camillo Marra; Diego Cecchin; Diego De Leo; Elena Marcello; Enrico Mossello; Fabio Gotta; Federica Agosta; Filippo Caraci; Gabriella Bottini; Giancarlo Logroscino; Giuseppe Bellelli; Giuseppe Bruno; Giuseppe Zappalà; Laura Bonanni; Leonardo Pantoni; Lorenzo Gaetani; Lorenzo Palleschi; Luca Roccatagliata; Lucilla Parnetti; Luisa Agnello; Marcello Ciaccio; Marco Bozzali; Mattia Altini; Mirco Cosottini; Nicoletta Gandolfo; Ovidio Brignoli; Pasquale Palumbo; Patrizia Mecocci; Patrizia Spadin; Raffaele Lodi; Sandro Sorbi; Silvia Morbelli; Sirio Cocozza; Sonia Francesca Calloni; Stefania Basilico; Stefano F Cappa; Walter Marrocco
|